92P - Validation of prognostic scores in small cell lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Small-Cell Lung Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Sacha Rothschild
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors S.I. Rothschild, R. Hagmann, A. Zippelius
  • Medical Oncology, Universitätsspital Basel, 4031 - Basel/CH

Abstract

Background

Treatment decisions in small-cell lung cancer (SCLC) are made based on the extent of the disease. However, the outcome differs among patients at the same stage. A simple tool to predict outcome in SCLC patients would be helpful for decision-making. In recent years, several prognostic scores have been proposed. However, most of them have never been validated in independent patient population.

Methods

From January 2000 to December 2010, 92 SCLC patients were treated at our institution. Data acquisition from consecutive patients was done through patients' medical records, and blood results recorded at the time of diagnosis. Univariate and multiple cox regression analyses of survival were performed to assess the prognostic value of relevant clinical and laboratory factors for SCLC. Furthermore, we investigated the relationship between seven published prognostic scores for SCLC and overall survival (OS).

Results

We recently published clinical data of our study population (Hagmann R. J Cancer 2015). In a univariate analysis, we evaluated 29 parameters. Staging (p 

Conclusions

We confirmed the prognostic role of the Manchester Score in an independent patient population whereas the reliability of more complex and recent scoring systems could not be validated. We therefore recommend using simple clinical and laboratory factors instead of complex scores to estimate prognosis of SCLC patients.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

University Hospital Basel

Disclosure

All authors have declared no conflicts of interest.